key: cord-1044246-5yqw7fea
authors: Nathwani, Rooshi; Mukherjee, Sujit; Forlano, Roberta; Mullish, Benjamin H.; Vergis, Nikhil; Selvapatt, Nowlan; Manousou, Pinelopi; Nayagam, Shevanthi; Lemoine, Maud; Dhar, Ameet
title: Letter: liver disease and COVID‐19—not the perfect storm
date: 2020-07-13
journal: Aliment Pharmacol Ther
DOI: 10.1111/apt.15872
sha: f84ecef62fb0b76ec0e097300445d568c0d9fb37
doc_id: 1044246
cord_uid: 5yqw7fea

LINKED CONTENT This article is linked to Garrido et al papers. To view these articles, visit https://doi.org/10.1111/apt.15813 and https://doi.org/10.1111/apt.15886.

We read with great interest the article by Garrido et al on COVID-19 and liver disease. 1 We agree that COVID-19 is associated with elevated liver enzymes, but its significance needs to be further elucidated as well as the impact of underlying liver disease on COVID-19. From 535 patients SARS-CoV-2 patients admitted at Imperial College Healthcare NHS Trust, London, from 25 February to 5 of April 2020, 2 we found 27.7% (148/535) had elevated liver transaminases. Median ALT and AST levels were 48 IU/L (IQR 17-49) and 88 IU/L (52-172) respectively. Only 1.7% (9/535) had an ALT five times the upper limit of normal and no patients developed synthetic liver dysfunction nor acute liver failure suggesting COVID-19 is not associated with significant acute liver injury. Patients with elevated liver transaminases had similar mortality rates than patients with normal transaminases at admission (29.4% vs 23.3%; P = 0.462), although a greater proportion with abnormal liver transaminases were admitted to intensive care (29.8% vs 10.7%; P < 0.001), in line with previous findings. 3 We also did not find a correlation between the degree of transaminitis and hypoxaemia on admission defined by a blood oxygen saturation level < 94% (r = 0.06, P = 0.42) suggesting no direct link between COVID-19-induced initial hypoxemia and liver damage.

In addition, we have explored the impact of pre-existing liver diseaseincluding cirrhosis, on the outcomes of COVID-19, which we feel is of great importance. Immune dysfunction has been well described in cirrhotic patients resulting in a high risk of infection and cirrhotic patients have poor outcomes with acute respiratory distress syndrome (ARDS). 4 In our cohort, 89/535 (16.6%) had suspected pre-existing liver disease based on radiological and laboratory results, including 21/535 (3.9%) with cirrhosis, supporting previously reported rates, 1 and 13/21 (61.9%) had decompensated cirrhosis (Child-Pugh B/C) ( Table 1 ). The main aetiology of cirrhosis was alcohol (47.6%). COVID-19 symptoms at admission, in cirrhotic patients, were mainly cough (71.4%), fever (57.1%) and shortness of breath (23.8%), rather than worsening features of hepatic decompensation. Following admission, 6/21 (28.6%) with compensated cirrhosis developed hepatic decompensation (ie new onset encephalopathy, ascites, variceal haemorrhage or jaundice). This hepatic decompensation rate was not higher than that observed in historical in-hospital pre-COVID cirrhosis data (28.6% vs. 37%). 5 The overall mortality of COVID-19 patients with cirrhosis was similar to those COVID-19 patients without liver disease (38.1% vs.

34.1%, P = 0.689). Median duration of admission was longer in cirrhotic patients compared to those without pre-existing liver disease (10 days vs. 7 days, P = 0.016), but development of ARDS requiring admission to ICU for intubation and ventilation was not statistically significant (5.3% vs. 13.7%, P = 0.280). At 14 days after diagnosis, hospital readmission rates for those with cirrhosis were comparable with those without liver disease (14.3% vs 11.8%, P = 0.78) and only one patient re-presented to hospital with bacterial superinfection.

To summarise, our findings suggest that: i. one third of COVID-19 patients have mild transaminitis, which may be associated with more severe disease but not increased mortality; ii. liver cirrhosis does not predispose to increase mortality but does increase length of stay.

Further outcome data from large registries of COVID-19 patients with cirrhosis are awaited to confirm this.

Declaration of personal interests: None. Letter: liver disease and COVID-19-not the perfect storm.

Dear Editors,

We read with great interest the letter by Nathwani et al 1 , commenting on our article on COVID-19 and liver disease 2 . They reported their experience in managing abnormal liver function tests during

underlying chronic liver disease. The authors concluded that mild serum elevations of aminotransferases were associated with more severe disease but not increased mortality. Additionally, they also reported that cirrhosis predisposes to increase in length of stay, although the overall mortality was similar to those without liver disease.

We agree that patients with cirrhosis would be of major concerns In conclusion, it is essential to make immediate contact after the appearance of signs or symptoms compatible with COVID-19 or decompensated cirrhosis for urgent referral and management.

Additionally, more intensive surveillance and individually tailored therapeutic approaches are needed for cirrhotic patients with SARS-CoV-2 infection. Further research identifying interventions to reduce poor outcomes in these patients is required.

Novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases

Letter: gastrointestinal ACE2, COVID-19 and IBD-opportunity in the face of tragedy?

Counter-regulatory 'Renin-Angiotensin' system-based candidate drugs to treat COVID-19 diseases in SARS-CoV-2-infected patients

Clinical outcomes in COVID-19 patients treated with tocilizumab: an individual patient data systematic review

Corticosteroids but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

The utility of fecal calprotectin in the era of COVID-19 pandemic

Faecal calprotectin indicates intestinal inflammation in COVID-19

Review article: Covid-19 and liver disease -what we know on 1st

Clinical characteristics and predictors of outcomes of hospitalised patients with COVID-19

Imperial College COVID-19 response team

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Liver cirrhosis is independently associated with 90-day mortality in ARDS patients

Hospital Re-admissions among patients with decompensated cirrhosis